CIMT
Updates
CIMT Annual Meeting 2012
10th CIMT Annual Meeting
May 23 - 25, 2012
Mainz, Germany
News
Volume 61 Number 5 is now available on SpringerLink.
The Faculty of Medicine at the University of Erlangen-Nürnberg, Department of Dermatology invites applications for a
W2-Professorship for Tumour Immunology (with focus on systems biology )
CIMT-CIP delegate joins Steering Committee of AACR-CIMM
Leiden, March 1, 2012
Dr. Sjoerd van der Burg, co-chair of the CIMT Immunguiding Program, has been appointed as member of the Steering Committee in the American Association for Cancer Research (AACR) Cancer Immunology Working Group (CIMM) for 2012-2014. The mission of the CIMM is to provide a forum for scientists and clinicians interested in cancer immunology and immunotherapy to meet, exchange knowledge and ideas, and discuss the present status and future promise of this important discipline, similar to that of CIMT.
The CIMM helps AACR to promote, integrate, and widely disseminate the new developments in cancer immunology and immunotherapy to the scientific community. Dr. van der Burg indicates that his appointment will allow him “to share the mission of CIP within the large community of scientists studying the immunology of cancer and encourage them to join the ongoing harmonization initiatives.”
10th CIMT Annual Meeting – Next-Generation Cancer Immunotherapies
Registration Is Now Open
Mainz, January 4 – As Europe’s largest meeting on cancer immunotherapy, CIMT 2012 will provide a stage for reflecting the knowledge of 10 years of cancer immunotherapy, presenting current scientific approaches and discussing next-generation therapies.
Highlights of the 10th anniversary meeting in Mainz, Germany, will be individualized therapy approaches and therapeutic antibodies. Sessions in therapeutic vaccination, cellular therapy and improving immunity will discuss new methods, tools, and results that are advancing our ability to generate immunotherapies and treat cancer patients. A dedicated session on immunomics presents insights in combining genomics, transcriptomics, systems biology and bioinformatics for the development and testing of immunotherapies.
In addition, CIP (CIMT Immunoguiding Program) and RRG (Regulatory Research Group) will hold sessions and panel discussions focusing on standardized and innovative tools for improving the quality of immunomonitoring and facilitating the translation of scientific knowledge to drug development.
Please see the CIMT 2012 meeting site for more information.
Independent Proficiency Panels Demonstrate Critical Value of Cross-Laboratory Assay Harmonization
Guiding and Improving Immune Response Measurements in Early Clinical Studies
Mainz, Germany and New York, NY, USA, Nov. 9, 2011 – The Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP) and the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) today announced the publication of a joint paper in Science Translational Medicine discussing recent results of independent international, cross-laboratory immune assay harmonization studies. More than 120 academic, pharmaceutical, biotechnology, contract research, and government laboratories from the United States and Europe have participated in CIMT-CIP and CRI-CIC sponsored proficiency panels to test and compare immune response assays, including measurement variability and reproducibility. The collaboration between both organizations dedicated to cancer immunotherapy has enabled this successful program, which represents the largest in the field and delivers an important practical advance to the research community.
CIMT 2011 Meeting Report in Cancer Immunology Immunotherapy
Issued online on November 3, 2011 in Cancer Immunology Immunotherapy, this meeting report summarizes presentations from the Ninth Annual Meeting of the Association for Cancer Immunotherapy (CIMT 2011) published together with a series of Focussed Research Reviews based on lectures given at the conference.
Collaborative Partnership Pioneers Model to
Improve Clinical Success of Cancer Immunotherapies
Joint White Paper Outlines New Methodological Framework to Guide Informed,
Reproducible Success in Cancer Immunotherapy Clinical Development
New York, NY, USA, and Mainz, Germany, Oct. 18, 2011 – The Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) and the Association for Cancer Immunotherapy (CIMT) have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer. Cancer immunotherapies that can safely and powerfully train patients’ immune systems to fight their tumors have the potential to fundamentally change the way that many, if not all, cancers are treated.
Mainz, June 1, 2011: Development and medical approval of novel cancer immunotherapy drugs were at the center of this year’s international meeting of the Association for Cancer Immunotherapy. The organizers reported attendance of more than 530 representatives from research institutes, hospitals, biotech and pharmaceutical industry around the world.
The CIMT Annual Meeting enabled attendees to exchange knowledge and ideas about new innovative cancer therapies that actively target the immune system of patients suffering from cancer. The meeting took place May 25-27.
“With a record number of international participants, the 2011 CIMT Annual Meeting proved to be the number one place in Europe to network and exchange ideas”, summarizes Cedrik Britten, CIMT Director of Translational Medicine. “At the gateway between immunological research and clinical translation, CIMT again offered the unique opportunity to meet the top protagonists of the field in one place.”
With offices in Mainz, Germany, CIMT is one of the leading European research and communication platforms for scientists, clinical doctors, industry representatives and regulatory officers who are shaping the field of cancer diagnostics and immunotherapy. The 2011 Mainz Annual Meeting showcased current developments in cancer medicines such as antibody and tumor vaccinations as well as discussions on international drug regulations and research harmonization.
February 2011: The Association for Cancer Immunotherapy (CIMT) has been granted society membership of the Federation of Clinical Immunology Societies (FOCIS). Effective immediately, CIMT and all CIMT Members can take full advantage of being a FOCIS Members Society including professional development resources and discounted registration fees at FOCIS events.
About FOCIS: The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001. After two successful consecutive meetings, FOCIS incorporated in 2003 as a 501(c)3 organization. Now in its ninth year of existence, FOCIS has 43 Member Societies, representing roughly 60,000 clinician scientists. A Federation of this size provides a voice for clinical immunologists and ultimately strives to improve patient care.
CIMT and CIC-CRI have submitted a joint commentary on the European Medicines Agency concept paper on the need to revise the guideline on the evaluation of anticancer medicinal products in man (EMA/EMA/CHMP/EWP/433478/2010).
View the submitted commentary by CIMT and CIC-CRI.
What would you like to do?
We are committed to the education of scientists and clinicians. This website offers information on our organization and its work. CIMT hosts two working groups and holds an annual meeting dedicated to cancer immunotherapy research and development. We work as a non-profit organization and depend on donations and financial support. Read here on how to get involved or drop us a line.
